Portal de Periódicos da CAPES

Prognostic significance of EZH 2 expression in patients with oesophageal cancer: a meta‐analysis

2016; Wiley; Volume: 20; Issue: 5 Linguagem: Inglês

10.1111/jcmm.12791

1582-4934

Yawei Wang, Fang Gao, Meng Zhao, Bing Li, Dan Xing, Jie Wang, Yang Yang,

Pancreatic and Hepatic Oncology Research

Abstract Enhancer of zeste 2 ( EZH 2), a key component of polycomb repressive complex 2 ( PRC 2), was of great importance in human cancer pathogenesis. Various studies examined the relationship between EZH 2 overexpression with the clinical outcome in patients with digestive cancers, but yielded conflicting results. Electronic databases updated to January 2015 were searched to find relevant studies. A meta‐analysis was conducted with eligible studies which quantitatively evaluated the relationship between EZH 2 overexpression and survival of patients with digestive cancers. Survival data were aggregated and quantitatively analysed. We performed a meta‐analysis of 10 studies ( n = 1461 patients) that evaluated the correlation between EZH 2 overexpression and survival in patients with digestive cancers. Combined hazard ratios suggested that EZH 2 overexpression was associated with poor prognosis of overall survival ( HR = 1.54, 95% CI : 1.27–1.81) in patients with oesophageal cancer. In the stratified analysis, no significant risks were found among gastric cancer ( HR = 0.66, 95% CI : 0.16–1.15) and colorectal cancer ( HR = 0.91, 0.63–1.19), indicating that EZH 2 was not an indicator of poor prognosis in gastric cancer or colorectal cancer. Enhancer of zeste 2 overexpression indicates a poor prognosis for patients with oesophageal cancer, but not among gastric cancer or colorectal cancer.